Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Friday, plunged -2.91% from the previous trading day, before settling in for the closing price of $5.16. Within the past 52 weeks, XERS’s price has moved between $1.72 and $6.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 197.66% annually for the last half of the decade. The company achieved an average annual earnings per share of 85.82%. With a float of $147.66 million, this company’s outstanding shares have now reached $156.01 million.
In an organization with 394 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 79.19%, operating margin of -16.57%, and the pretax margin is -28.12%.
Xeris Biopharma Holdings Inc (XERS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 7.80%, while institutional ownership is 43.24%. The most recent insider transaction that took place on May 09 ’25, was worth 277,668. Before that another transaction happened on Mar 20 ’25, when Company’s insider sold 40,000 for $5.43, making the entire transaction worth $217,244. This insider now owns 1,353,510 shares in total.
Xeris Biopharma Holdings Inc (XERS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 85.82% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.17 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.30, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.11 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Let’s dig in a bit further. During the last 5-days, its volume was 2.84 million. That was better than the volume of 2.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 71.67%. Additionally, its Average True Range was 0.32.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 63.82%, which indicates a significant decrease from 79.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.68% in the past 14 days, which was higher than the 61.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.63, while its 200-day Moving Average is $3.50. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $5.16. Second resistance stands at $5.31. The third major resistance level sits at $5.39. If the price goes on to break the first support level at $4.93, it is likely to go to the next support level at $4.85. Assuming the price breaks the second support level, the third support level stands at $4.70.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 771.24 million based on 156,385K outstanding shares. Right now, sales total 203,070 K and income totals -54,840 K. The company made 60,100 K in profit during its latest quarter, and -5,110 K in sales during its previous quarter.
